10-Q: PROCEPT BioRobotics Q1 2026 Financial Results

PROCEPT BioRobotics reports 20% revenue growth to $83.1 million for Q1 2026, driven by increased system sales and utilization.

Summary

• Revenue reached $83.1 million for the first quarter of 2026, a 20% increase compared to $69.2 million in the same period of 2025.
• Net loss for the quarter was $31.6 million, compared to a net loss of $24.7 million in Q1 2025.
• The company maintains an install base of 971 robotic systems globally, with 765 located in the United States.
• Gross margin improved to 65% in Q1 2026, up from 64% in Q1 2025, benefiting from increased production scale.
• Operating expenses rose to $86.6 million, reflecting continued investment in R&D and commercial expansion.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid operational quarter with strong revenue growth and margin expansion, though the widening net loss reflects the aggressive investment phase typical of a growth-stage medical technology company.

Positives

• Revenue growth of 20% year-over-year demonstrates strong market demand for Aquablation therapy.
• Gross margin expansion to 65% indicates improved manufacturing efficiencies and pricing power.
• Successful expansion of the global install base to 971 systems.
• Strong cash position of $245.6 million as of March 31, 2026, providing sufficient runway for at least the next twelve months.

Negatives

• Net loss widened to $31.6 million from $24.7 million in the prior year period.
• Operating expenses increased by 21% to $86.6 million, driven by higher R&D and SG&A spending.
• Cash and cash equivalents decreased from $286.5 million at year-end 2025 to $245.6 million at the end of Q1 2026.

Risks

• Continued reliance on third-party payors for reimbursement and coverage of procedures.
• Exposure to market risks including interest rate fluctuations and foreign currency exchange rates.
• Potential for increased competition from alternative surgical technologies.
• Dependence on global suppliers for components and sub-assemblies.
• Risks associated with the ongoing need for significant capital to fund R&D and commercial growth.

Future Outlook

Management expects revenue to increase in absolute dollars for the foreseeable future as they focus on driving adoption and system utilization, though results may fluctuate quarterly. The company plans to continue investing in R&D for next-generation technologies and expanding its commercial infrastructure.

Management Comments

• Management believes Aquablation therapy represents a paradigm shift in the surgical treatment of BPH.
• The company expects to leverage clinical evidence and KOL networks to establish Aquablation as the surgical standard of care.
• Management anticipates that increased production volume will continue to improve gross margins over the long term.

Industry Context

StockSavvy.ai notes that the surgical robotics sector remains highly competitive, with companies increasingly focusing on AI-integrated surgical planning and data-driven outcomes to differentiate their platforms from traditional surgical methods like TURP.

Comparison to Industry Standards

• The company's focus on BPH treatment places it in direct competition with established urological device manufacturers.
• The 65% gross margin is competitive within the medical device sector, reflecting the high-margin nature of the disposable handpiece business model.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company pursues additional equity financing.
• Customers benefit from the continued expansion of clinical evidence and support for Aquablation therapy.

Next Steps

• Continue expansion of the direct capital sales representative team.
• Ongoing development of next-generation technologies and AI-integrated surgical planning.
• Active discussions with commercial payors to establish additional coverage policies.

Key Dates

Recommendation

The company is executing well on its growth strategy, but the ongoing net losses and potential for future dilution warrant a cautious hold until the company demonstrates a clearer path to profitability.

Keywords

surgical robotics, urology, Aquablation, BPH, medical devices, PROCEPT BioRobotics, PRCT